Skadden is representing Micrus Endovascular Corporation, which joined Johnson & Johnson on July 12 in announcing a definitive agreement whereby Micrus will be acquired in a cash-for-stock exchange. The value of the transaction is estimated to be $480 million, and the deal is expected to close before the end of the year. Micrus is a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates